Structure Therapeutics COO files Form 3

Structure Therapeutics Inc. executive Matthew Lang, who serves as COO & GC, has filed an initial Form 3 as a reporting person.

Accepted by SEC EDGAR 04/23/2026 - 04:19 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Structure Therapeutics Inc. executive Matthew Lang, who serves as COO & GC, has filed an initial Form 3 as a reporting person. The filing shows no reported purchases, sales, gifts, tax withholdings, restructurings, or derivative exercises, and includes no derivative holdings in the excerpt provided.

Key Figures

Reported share purchases: 0 shares Reported share sales: 0 shares Net buy/sell direction: neutral

3 metrics

Reported share purchases 0 shares Form 3 transaction summary buyShares

Reported share sales 0 shares Form 3 transaction summary sellShares

Net buy/sell direction neutral Form 3 transaction summary netBuySellDirection

Key Terms

Form 3, reporting person, derivativeSummary

3 terms

Form 3 regulatory

"INSIDER FILING DATA (Form 3): {"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

reporting person regulatory

""reportingPersons": [ { "name": "Lang Matthew""

derivativeSummary financial

""derivativeSummary": [],"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Structure Therapeutics (GPCR) Form 3 for Matthew Lang show?

The Form 3 for Matthew Lang, COO & GC of Structure Therapeutics, is an initial report of beneficial ownership. In the provided data, it shows no reported transactions and no listed derivative positions.

Did Matthew Lang buy or sell Structure Therapeutics (GPCR) shares in this Form 3?

No transactions are reported in this Form 3. The transaction summary shows zero purchases, zero sales, zero gifts, and zero tax-withholding or restructuring transactions for Matthew Lang.

Does the GPCR Form 3 disclose any option or derivative positions for Matthew Lang?

The derivative summary in this Form 3 is empty. This means the excerpted data does not list any unexercised options, warrants, or other derivative securities for Matthew Lang in this filing.

What insider role does Matthew Lang hold at Structure Therapeutics (GPCR)?

Matthew Lang is identified as an officer of Structure Therapeutics, with the title "COO & GC." He is not flagged as a director or a ten-percent owner in the Form 3 metadata.

Does the Structure Therapeutics Form 3 indicate net buying or selling activity?

No. The transaction summary shows netBuySellShares of 0 and a netBuySellDirection labeled "neutral," indicating no net buying or selling activity in the reported data.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Lang Matthew

(Last) (First) (Middle)

C/O STRUCTURE THERAPEUTICS INC.

601 GATEWAY BLVD., SUITE 900

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
04/15/2026

3. Issuer Name and Ticker or Trading Symbol
Structure Therapeutics Inc. [ GPCR ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	COO & GC

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ Jun Yoon, Attorney-in-Fact	04/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)